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Introduction: The therapeutic potential of acyclic retinoid (ACR), a synthetic retinoid, has been confirmed in
experimental and clinical studies. Therapeutic targets include precancerous and cancer stem cells. As ACR is also
involved in developmental processes, its effect on normal hepatic stem cells (HpSCs) should be investigated for
understanding the underlying mechanisms. Here, we examined effects of the acyclic retinoid peretinoin on fresh
isolated murine HpSCs.
Methods: We isolated c-kit−CD29+CD49f+/lowCD45−Ter119− cells from murine fetal livers using flow cytometry. To
evaluate the effect of ACR, we traced clonal expansion and analyzed cell differentiation as well as apoptosis during
the induction process by immunofluorescent staining and marker gene expression.
Results: ACR dose-dependently inhibited HpSCs expansion. Stem cell clonal expansion was markedly inhibited
during the culture period. Moreover, ACR showed a significant promotion of HpSC differentiation and induction of
cellular apoptosis. The expression of stem cell marker genes, Afp, Cd44, and Dlk, was downregulated, while that of
mature hepatocyte genes, Alb and Tat, and apoptosis-related genes, Annexin V and Caspase-3, were upregulated.
Flow cytometry showed that the proportion of Annexin V-positive cells increased after ACR incubation compared
with the control. Data obtained by immunofluorescent staining for albumin and Caspase-3 corroborated the data
on gene expression. Finally, we found that ACR directly regulates the expression of retinoic acid receptors and
retinoid X receptors.
Conclusions: These findings indicate that ACR inhibits the clonal expansion of normal HpSCs in vitro and promotes
the differentiation of immature cells by regulating receptors of retinoic acid.Introduction
Retinoic acid, a natural derivative of the metabolism of
vitamin A, is an essential component of cell–cell signal-
ing in embryogenesis, growth, and differentiation [1].
Retinoic acids can directly enter the nucleus and regu-
late target genes via nuclear receptors, including retinoic
acid receptors (RARs) and retinoid X receptors (RXRs)
[2]. Early studies of vitamin A deficiency [3-5] and com-
pound RAR mutations [6,7] have indicated that retinoic
acids are essential for the development of several organs,
including the hindbrain, spinal cord, heart, eye, skeleton,
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unless otherwise stated.[1]. Recent studies suggest that retinoic acid can work in
a paracrine manner to control the differentiation of
pluripotent cells [8,9].
Peretinoin is a novel synthetic acyclic retinoid (ACR),
with a structure similar to that of natural retinoic acid,
that can bind to retinoid nuclear receptors such as RARs
and RXRs [10]. Clinical studies have found that ACR can
significantly reduce the incidence of post-therapeutic he-
patocellular carcinoma (HCC) recurrence and improve
the survival rate of HCC patients [11-14]. A phase II/III
randomized, placebo-controlled trial demonstrated that
600 mg/day peretinoin can reduce the risk of HCC recur-
rence or death by approximately 40% compared with pla-
cebo [15]. Moreover, ACR also inhibits the progression of
adult T-cell leukemia by inactivating nuclear factor-kB
[16] as well as pancreatic cancer by inhibiting Ras activa-
tion [17] in vitro and in vivo.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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research [18,19] and clinical studies [11,12]. It has been re-
ported that ACR exhibited the anti-HCC mechanism
through increasing cell apoptosis [19,20] and inhibiting cell
proliferation [21,22]. Further, Yasuda and colleagues [19]
found that ACR could induce the production of albumin
and reduce AFP-L3 levels in hepatoma-derived cell lines.
These data may indicate that ACR can promote HCC
differentiation to exhibit the anti-HCC effect. Our previous
studies have demonstrated that ACR can inhibit the devel-
opment of precancerous cells in HCC models [23], while
the role of ACR in normal hepatic stem cells (HpSCs)
remains unclear.
During liver development, fetal HpSCs can be devel-
oped from the foregut endodermal cells, and they differ-
entiate into liver cell lineage, including hepatocytes and
cholangiocytes [24,25]. Our previous study has identified
the population of fetal HpSCs as c-Kit−CD29+CD49f+/low
CD45−Ter-119− [26]. Retinoic acid has played a signifi-
cant role in organ development [1], whereas the role of
ACR in liver regeneration it is still unclear [27-29]. Fur-
thermore, as hepatic carcinogenic stem cells exhibit char-
acteristics similar to normal HpSCs [30], a comprehensive
understanding of the role of ACR in normal HpSCs would
enable us to explore the mechanisms and functions of
ACR in liver development and regeneration as well as in
hepatic carcinogenesis. Although hepatic stem/progeni-
tor cells in the developing liver have been extensively
characterized [26], it is still under debate whether HpSCs
exist in adult tissue, especially in recent studies [31,32].
Although these cells may not represent an important
source of regeneration in vivo, their expandability and
hepatocytic potential still make them an attractive poten-
tial source of liver cells for regenerative medicine [24,25].
In this study, the murine fetal HpSC subpopulation,
c-kit−CD29+CD49+/lowCD45−Ter119− cells, were isolated
by flow cytometry as previously described [33]. And we
examined the effects of ACR on fetal HpSCs, including
clonal colony expansion, differentiation, and apoptosis as
well as on retinoic acid-related receptors.
Materials and methods
Animals and ethics
Embryonic day 13.5 C57BL/6 J mice were purchased from
Japan SLC Inc. (Shizuoka, Japan). Animal experimental
work was conducted in accordance with the Guidelines for
Proper Conduct of Animal Experiments (Science Council of
Japan), and all experimental procedures were approved by
the institutional review board of Animal Research Center,
Yokohama City University School of Medicine (No.11–68).
Hepatic stem cell isolation
Suspended liver cells were obtained from embryonic day
13.5 C57BL/6 fetal mice as previously described [33]. Inbrief, dissociated liver cells were stained with biotinyl-
ated anti-CD45 and Ter-119 monoclonal antibodies,
anti-CD29-FITC antibody, anti-CD49f-PE antibody, and
anti-c-Kit-APC antibody. Cells positive for the biotinyl-
ated antibodies were detected with streptavidin-labeled
allophycocyanin-Cy7 (all monoclonal antibodies were
purchased from BD PharMingen, San Diego, CA, USA).
Labeled cells were then analyzed and separated using
MoFlo (DakoCytomation, Denmark) and Summit ver-
sion 4.0 software (DakoCytomation, Denmark).Cell culture
Sorted cells were seeded on type IV collagen-coated
dishes (Becton Dickinson, San Jose, CA, USA) using our
standard culture medium. Williams’ Medium E (Gibco,
Grand Island, NY, USA) was supplied with 10% fetal bo-
vine serum (MP Biomedicals, LLC, Solon, OH, USA),
1 μg/mL insulin (Wako, Osaka, Japan), 1 × 10−7 M dexa-
methone (Sigma, St Louis, MO, USA), 10 mmol/L nicotina-
mide (Sigma), 2 mmol/L L-glutamine (Gibco), 50 mmol/L
HEPES (Wako), 50 mmol/L β-mercaptoethanol (Sigma),
50 ng/mL hepatocyte growth factor (Sigma), 20 ng/mL epi-
dermal growth factor (Sigma), and 100 U penicillin/
streptomycin (Gibco). Cells were cultured at 37°C in a hu-
midified atmosphere of 5% CO2.
ACR as peretinoin was provided by Kowa (Tokyo, Japan),
and resolved in dimethyl sulfoxide (DMSO). For the half
maximal inhibitory concentration (IC50) experiment, the
medium was supplemented with ACR after 24 hours of cul-
ture, and the final concentrations were 0, 0.5, 1.0, 2.0, 4.0,
and 8.0 mg/L. The same concentration of DMSO was used
in the controls. The medium was changed every other day.
After 7 days of culture, cell number and colonies were
counted. After determination of the IC50 dose, all following
experiments were supplemented with this dose.
For assessing the colony expansion and proliferation
of HpSCs, the IC50 dose (3.5 mg/L ACR with 0.05%
DMSO) was added to cultures after 24 hours. The same
concentration of DMSO was used in the controls. Single
cell growth was traced at days 0, 1, 3, 5, and 7. The col-
ony size and the frequency of colony formation were
traced and calculated after 7 days of culture (colonies
containing >10 cells were counted).
For experiments on the vacuolar degeneration of
HpSCs, 3.5 mg/L ACR with 0.05% DMSO was added to
cultures after 72 hours, and the formation of vacuolar cells
was detected after 24 hours of incubation with ACR. The
same concentration of DMSO was used in the controls.
For the other experiments, 24 cultures were supple-
mented with the IC50 dose (3.5 mg/L ACR with 0.05%
DMSO) with the same concentration of DMSO used in
the controls. After 5 days of culture, cells were harvested
for immunofluorescence studies and RNA isolation.
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Culture cells were fixed with 4% paraformaldehyde in a
6-well plate at 4°C for 15 minutes, washed three times
with phosphate-buffered saline containing 0.05% Tween
20 (Wako), blocked with 10% normal goat serum,
followed by overnight incubation with Alb (Biosciences,
Cambridge, UK), Ki67 (Abcam, Cambridge, MA, USA),
or Cleaved Caspase-3 (Asp175) Antibody (Cell Signaling
Technology, Beverly, MA, USA). Next, cells were incu-
bated with 488- or 555-labeled secondary antibodies for
2 hours. After the final washing, nuclei were stained blue
with DAPI and viewed with a Zeiss Axio Imager.M1
microscope (Carl Zeiss, Germany).
RNA isolation and real-time polymerase chain reaction
Total RNA was isolated using ISOGEN (Nippon gene,
Tokyo, Japan) according to the manufacturer’s instructions.
A total of 1 μg RNA was used as the template for single
strand cDNA synthesis utilizing random primers and the
SuperScriptIII Reverse Transcriptase (Invitrogen, Carlsbad,
CA, USA). cDNA was amplified using SYBR green PCR
Mix (Takara, Otsu, Japan) on the ABI PRISM 7900 real-
time PCR system (Applied Biosystems, Foster City, CA,
USA), programmed for 95°C for 2 minutes, followed by
40 cycles of 95°C for 10 seconds, and 60°C for 50 seconds.
Amplification results were analyzed using RQ Manager 1.2
(Applied Biosystems) and the gene of interest was normal-
ized to the corresponding 18S results. An additional primer
sequence lists this in more detail (see Additional file 1).
Apoptosis analysis
After 5 days of culture, mouse fetal HpSCs were har-
vested with 0.05% trypsin (Sigma). Cells were washed
with phosphate-buffered saline and cellular apoptosis was
detected by Annexin-V FLUOS staining kit (Roche Diag-
nostics, Indianapolis, IN, USA) according to the manufac-
turer’s instructions. Samples were stained with 10 μg/mL
propidium iodide in the dark at 4°C for 10 minutes.
Annexin V-positive cells were analyzed with MoFlo and
the Summit version 4.0 software (both DakoCytomation).
Statistical evaluation
Values are expressed as mean ± SD. Statistical analysis
was performed using Mann–Whitney U test to compare
the mean values between two groups. Values of P < 0.05
are considered to be statistically significant.
Results
Hepatic stem cell isolation and dose-dependent response
to acyclic retinoid
To investigate the role of ACR on HpSCs, we sorted HpSCs
from embryonic day 13.5 fetal mouse liver with HpSC
markers as reported (c-Kit−CD29+CD49f+/lowCD45−Ter-
119−) (Figure 1A), as such cells show strong self-renewaland colony formation capabilities (Figure 1C). ACR exerts
its function through the retinoid-related receptors, includ-
ing RARs and RXRs. As shown in Figure 1B, the expression
of RARs (Rarα and Rarβ) and RXRs (Rxrα and Rxrβ) could
be detected in HpSC, except Rarγ and Rxrγ. Compared
with adult liver, HpSCs showed a higher expression of Rarα,
Rxrα, and Rxrβ but a lower expression of Rarβ. To deter-
mine the role of ACR on HpSCs, we treated HpSCs with
different concentrations of ACR, including 0, 0.5, 1.0, 2.0,
4.0, and 8.0 mg/L. After 7 days of culture, the numbers of
total cells and colonies had significantly decreased in the
cell population incubated with ACR, and the decrease was
dose dependent (Figure 1C and D). The IC50 of ACR on
HpSCs was calculated to 3.5 mg/L.
Acyclic retinoid inhibits clonal expansion and
proliferation of hepatic stem cells
To further evaluate the role of ACR on HpSCs, we used
the IC50 dose of ACR to trace the clonal expansion of
HpSCs. As shown in Figure 2A and B, HpSCs demon-
strated high self-renewal capacity and colony formation
capability; the colony-forming efficiency was as high as
1.32% (with values up to 132.16 ± 15.02 per 10,000
plated cells), with large average colony sizes, including
42.18 ± 6.50 cells per colony (Figure 2C), while the self-
renewal and colony formation capacities were signifi-
cantly inhibited by ACR. After ACR treatment, the
clonal expansion of HpSCs almost stopped, the colony
number decreased to 8.4% compared to the control
(11.11 ± 1.59 per 10,000 plated cells), and colony sizes
were only 38% the size of the control, with 16.15 ± 1.98
cells per colony (Figure 2C). To probe the role of ACR
in the inhibition of clonal expansion, we examined the
Ki-67-positive cells after incubation with ACR. After incu-
bation with ACR, the Ki-67-positive cells in HpSC-derived
colonies significantly decreased from 12.51 ± 1.95% to
3.35 ± 0.86% (Figure 2D). To further confirm the inhib-
ition of colony expansion and proliferation by ACR, we
analyzed the expression of the cell cycle-related genes,
p21cip1 and Cyclin D1. The expression of p21cip1 increased
by 6.8-fold in ACR-treated cells (see Additional file 2), and
hence were clearly different in gene expression (P < 0.05),
while the expression of Cyclin D1 was significantly down-
regulated (see Additional file 2).
Acyclic retinoid promotes differentiation of hepatic
stem cells
To investigate the role of ACR in colony expansion and
proliferation, we hypothesized that ACR can induce the
differentiation of HpSCs. After 5 days of culture, 3.60 ±
0.82% HpSCs were albumin positive (Figure 3A), while
the percentage among ACR-treated cells was 19.44 ±
6.13% (Figure 3A). The related gene expression also indi-








Figure 1 Hepatic stem cell isolation and dose-dependent response to acyclic retinoid. (A) Hepatic stem cells (HpSCs) were sorted by flow
cytometry using the gate c-Kit−CD29+CD49f+/lowCD45−Ter-119−. (B) The expression of Rarα, Rarβ, Rxrα, and Rxrβ in adult liver (AL; n = 3), fetal liver
(FL; n = 3), fetal liver cell (FLC; n = 3), and HpSCs (n = 3). (C) Acyclic retinoid (ACR) inhibited the growth of HpSCs with different concentrations
(0, 0.5, 1.0, 2.0, 4.0, and 8.0 mg/L). Scale bar = 200 μm. (D) Relative numbers of HpSCs and numbers of HpSC colonies in different concentrations
of ACR after 7 days of culture (n = 3). Data are shown as means ± SD. Mann–Whitney U-test. *P < 0.05; **P < 0.01.
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were significantly downregulated by ACR (Figure 3B),
and the mature hepatic genes, Alb and Tat, were signifi-
cantly upregulated after ACR treatment (Figure 3C).
HpSCs can also differentiate into bile duct cells, while
the expression of the bile duct cell marker gene, Ck-19,
was inhibited by ACR (Figure 3C). These data indicate
that ACR promotes the hepatocellular but not cholan-
giolar differentiation of HpSCs.Acyclic retinoid induces cellular apoptosis of hepatic
stem cells
Apoptosis can be another cause of the inhibition of
clonal expansion. Twenty-four hours after adding ACR,
we observed the appearance of vacuolar cells (Figure 4A;
approximately 89.17 ± 4.79% of the cells were vacuolar),
while only 5.42 ± 2.52% of the cells not incubated with
ACR were vacuolar (Figure 4A). ACR significantly in-
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Figure 2 Acyclic retinoid inhibits clonal expansion and proliferation of hepatic stem cells. (A) Tracing colony expansion of hepatic stem
cells (HpSCs) with half maximal inhibitory concentration dose (3.5 mg/L) of acyclic retinoid (ACR) during 7 days of culture. (B) Tracing the
proliferation of HpSCs during 7 days of culture treated with ACR (n = 6). (C) The number and size of colonies formed at day 5 of ACR treatment
(n = 6). (D) Immunofluorescence for Ki-67 after treatment with ACR, and statistical data of percentage of Ki-67 positive cells (n = 6). Scale bar = 200
μm. Data are shown as means ± SD. Mann–Whitney U-test. *P < 0.05; **P < 0.01.
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in Figure 4B, we found that ACR markedly elevated the
percentage of Caspase 3-positive cells from 2.96 ± 0.27%
to 35.68 ± 5.05%. To further confirm the apoptosis
process induced by ACR, we analyzed the relative distri-
bution of Annexin V-positive cells with or without ACR
incubation. Without ACR incubation, Annexin V-positive
cells only amounted to 2.00 ± 1.30%, while the percentagesignificantly increased to 8.11 ± 3.10% after ACR incuba-
tion (Figure 4C). Moreover, we compared the expression
of apoptosis-related genes, Caspase 3 and Annexin V, with
and without ACR incubation. After incubation with ACR,
Caspase 3 was shown to be 7.55-fold enhanced, indicating
a significant difference in the expression (Figure 4D). The
increased expression of Annexin V in ACR-treated cells
was not significant (Figure 4D).
**
Figure 3 Acyclic retinoid promotes differentiation of hepatic stem cells. (A) Immunofluorescence for albumin (ALB) after treatment with
acyclic retinoid (ACR), and percentage of ALB-positive cells (n = 6). Scale bar = 200 μm. (B) Real-time PCR analysis of the relative mRNA expression
of Afp, Cd44, Dlk, and Epcam after treatment with ACR (n = 5 to 8). (C) Real-time PCR analysis of the relative mRNA expression of Alb, G6p, Ck19,
and Tat after treatment with ACR (n = 3 to 8). Data are shown as means ± SD. Mann–Whitney U-test. *P < 0.05; **P < 0.01.
Guan et al. Stem Cell Research & Therapy  (2015) 6:51 Page 6 of 11Acyclic retinoid regulates Rars and Rxrs expression in
hepatic stem cells
ACR exerts its functions through the retinoid-related re-
ceptors, RARs and RXRs; therefore, the regulation of
RARs and RXRs could also influence the function of
ACR. We previously found that HpSCs exhibit the ex-
pression of Rarα, Rarβ, Rxrα, and Rxrβ (Figure 1B). In
order to test the hypothesis that these receptors are reg-
ulated by ACR, performing special functions on HpSCs,we treated HpSC-derived colonies with ACR, and quan-
titated the expression of Rarα, Rarβ, Rxrα, and Rxrβ. As
shown in Figure 5A, we found that ACR clearly inhibited
the expression of Rarα, Rxrα, and Rxrβ, by a 2.45-, 2.86-,
and 2.56-fold decrease, respectively. However, the ex-
pression of Rarβ was significantly enhanced by ACR,
showing a 3.04-fold increase. The considered schematic
model for the role of ACR in HpSCs is summarized and
profiled in Figure 5B.
Figure 4 Acyclic retinoid induces cellular apoptosis of hepatic stem cells. (A) Observation of the formation of vacuolar cells after 24 hours
of incubation with acyclic retinoid (ACR), and the ratio of vacuolar cells (n = 9). (B) Immunofluorescence for Caspase 3 after incubation with
ACR, and the ratio of Caspase 3-positive cells (n = 6). (C) Flow cytometry analysis of Annexin V-positive cells after incubation with ACR (n = 3).
(D) Real-time PCR analysis of the relative mRNA expression of Annexin V and Caspase 3 after incubation with ACR (n = 5–8). Scale bar = 200 μm.
Data are shown as means ± SD. Mann–Whitney U-test. *P < 0.05; **P < 0.01.
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A previous study reported that ACR accelerated liver re-
generation following partial hepatectomy in a rat model
[29], and it was observed that hepatocyte DNA synthesis
was enhanced by ACR. All-trans retinoic acid (ATRA), a
natural retinoid, was also shown to accelerate liver re-
generation through the induction of the cell cycle genes
(Cyclin A, Cyclin B, Cyclin D, and Cyclin E), and increase
the proliferation of hepatocytes [35]. In the present study,
we focused on the role of the ACR peretinoin on fresh iso-
lated HpSCs in developing livers. We found that ACRinhibits clonal expansion and induces the differentiation
of HpSC-derived colonies accompanied by the downregu-
lation of the cell cycle-related gene, Cyclin D1. This differ-
ence in the role of ACR and ATRA in cell cycle regulation
and DNA synthesis results from the biphasic dose–
response relationship of ACR. In fact, low-dose ACR pro-
motes hepatocyte proliferation and DNA synthesis and
stimulates liver regeneration, whereas higher doses
actually reduce liver regeneration and decrease DNA syn-
thesis. In contrast, ATRA dose-dependently stimulates
liver regeneration [29]. Although ACR shares some
Figure 5 Acyclic retinoid regulates Rars and Rxrs expression in hepatic stem cells. (A) Real-time PCR demonstrated the relative mRNA
expression of Rarα, Rarβ, Rxrα, and Rxrβ in hepatic stem cells (HpSCs) after incubation with or without acyclic retinoid (ACR; n = 3). (B) Schematic
model for the role of ACR in HpSCs. ACR binds to the retinoic acid receptor (RAR) thereby transactivating genes through the retinoic acid responsive
element, or by binding to the retinoid X receptor (RXR) and transactivating genes via the retinoid X responsive element. Subsequently, ACR induces
differentiation, inhibits proliferation, arrests cell cycle, and promotes apoptosis in HpSCs through the related gene regulation. Furthermore, ACR
regulates the receptor genes, Rarα, Rarβ, Rxrα, and Rxrβ and enhances ACR action. Data are shown as means ± SD. Mann–Whitney U-test.
*P < 0.05; **P < 0.01.
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it has been reported that ACR differs in several biological
effects from ATRA [36-38]. ACR might mediate different
mechanisms of action to that of the natural retinoids in
stimulating normal hepatocyte proliferation. However, this
still remains to be elucidated.
ACR is known as a powerful agent in the clinical ther-
apy of HCC through increasing cell apoptosis [19,20], in-
duction of cell differentiation [19,39] and suppression of
cellular proliferation [21,22]. Our data show that ACR
could also induce cellular apoptosis, promote the differ-
entiation into hepatocytes, and inhibit clonal expansion
and proliferation. The schematic model is presented as
Figure 5B. The precise mechanism of ACR-induced
apoptosis is still not well understood. In part, the theory
is that nuclear retinoid receptors are ligand-dependent
transcription factors that bind to RAR or RXR elements
in the promoter regions of retinoid responsive target
genes [2]. There is an increase in the RARβ and
p21CIP1 proteins and their corresponding mRNAs anda decrease in the hyperphosphorylated form of the ret-
inoblastoma protein and subsequently a decrease in both
cyclin D1 protein and mRNA. After inhibition of the
transcriptional activity of the cyclin D1, c-fos, and acti-
vator protein promoters, there is an increase of cells in
G0-G1 phase and apoptosis is induced [40]. RARβ might
be an intermediate in a signaling cascade induced by ret-
inoic acid which ultimately activates a tumor-specific
apoptosis program mediated by tumor necrosis factor-
related apoptosis-inducing ligand [41]. However, given
the fact that RARβ2 is suppressed at early stages of car-
cinogenesis, agonists will be useful only in combination
with agents able to reverse the silencing of RARβ2 [41].
In addition, it is also reported that polyinosinic:polycy-
tidylic acid-mediated activation of Toll-like receptor 3
(TLR3) induces microRNAs targeting DNA methyltrans-
ferases, leading to demethylation and re-expression of
RARβ [42]. As a result, cancer cells become sensitive to
retinoic acid and undergo apoptosis both in vitro and
in vivo [42]. This study provides evidence of an
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and the biological rationale for a combined TLR3 agonist/
retinoic acid treatment of prostate and breast cancer [42].
Furthermore, ACR could perform similar functions on
HpSCs in HCC. The similarity may suggest a close rela-
tionship between HpSCs, HCC, and liver cancer stem
cells. Evidence exists that normal stem cells can be re-
programmed into cancer stem cells [43]. Chiba and col-
leagues reported that HCC could be initiated from
normal HpSCs by the overexpression of the Bmi-1 gene
[44]. Moreover, our previous study has identified precan-
cerous cells in rat hepatic oval cells fraction, and ACR
directly prevents de novo HCC by inhibiting the devel-
opment of the precancerous stem cells [23]. Since nor-
mal stem cells shared some common characteristics with
precancerous stem cells with regard to their response to
ACR, the result may indicate that ACR not only exhibits
the anti-tumor factor in HCC but also exerts the inhib-
ition on tumor original cells, liver cancer stem cells, and
precancerous cells. Researchers hypothesized that ACR
inhibits the development of HCC through the “clonal
deletion” method [10]. Our data show that the clonal ex-
pansion of HpSCs was inhibited by ACR and thereby
partly verifies the “clonal deletion” hypothesis.
Retinoids exert their biological effects through distinct
retinoid-related receptors. ATRA and 13-cis-retinoic
acid are likely to act mainly through RARβ [45]; 9-cis-
retinoic acid always activates RXRα [46] and ACR has
been reported to exert its biological function through
RARβ [22,47]. Moreover, ACR increased the expression
of RARβ in normal cells and HCCs, and induced apop-
tosis, while ACR did not regulate the expression of other
retinoid-related receptors [22,47]. In the present study,
we also observed the different expression of Rars and
Rxrs in adult liver and HpSCs. These results indicate
that the expression of Rars and Rxrs are related to the
degree of differentiation. Compared with adult hepatic
cells (highly differentiated), HpSCs (poorly differenti-
ated) show a higher expression of Rarα, Rxrα, and Rxrβ
and a lower expression of Rarβ. Abnormalities of RARs
and RXRs are also related to HCC [48,49]. The expres-
sion of RARα and RXRα were clearly increased [48,49]
and RARβ was markedly suppressed in human HCC
and HCC cell lines [48]. Moreover, we found that
RARα, RXRα, and RXRβ showed higher expression, while
RARβ showed lower expression in colon carcinoma cells
(poorly differentiated), the normal colon (highly differenti-
ated) being the control (data not shown). ACR could regu-
late the expression of Rars and Rxrs in HpSCs. After
incubation with ACR, the expression of Rarβ was promoted
and apoptosis was induced in HpSCs and the derived col-
onies. ACR can inhibit the expression of Rarα, Rxrα, and
Rxrβ; it exhibits a special effect on HpSCs to promote the
differentiation of HpSC-derived cells through regulatedRars and Rxrs. Immature cell types might respond to ACR
if its expression is high for the receptors no matter whether
they are from the normal or diseased tissue; this should
contribute to the understanding of the mechanism of action
of ACR and enhance or relate to treatments in other imma-
ture tissues, such as other cancerous or precancerous tis-
sues. This may suggest that ACR is an effective drug
candidate in clinical colon carcinoma therapy. Moreover,
the expression of Rars and Rxrs would be diagnostic
markers applicable to ACR in clinical carcinoma therapy.
Conclusions
In this study, we found that ACR can regulate the ex-
pression of related genes to inhibit clonal expansion and
proliferation, promote differentiation, and induce apop-
tosis in HpSCs. Moreover, ACR can regulate the expres-
sion of Rars and Rars in HpSCs, and Rars and Rxrs may
directly affect proliferation, differentiation, and apoptosis
in HpSCs (Figure 5B). In conclusion, ACR promoted the
differentiation of HpSCs, and ACR could also induce
apoptosis in HpSCs and in smooth muscle cells [47]
through Rars and Rxrs. Future studies on the roles of
Rars and Rxrs will help to further explore the application
of ACR in clinical carcinoma therapy.
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